Alydia Health is a technology company.
Alydia Health has raised $24.0M across 2 funding rounds.
Alydia Health has raised $24.0M in total across 2 funding rounds.
Alydia Health has raised $24.0M in total across 2 funding rounds.
Alydia Health's investors include Adjuvant Capital, Fusion Fund, Sonder Capital, Maurice Ferre.
# Alydia Health: A Medical Device Company, Not a Technology Company
Alydia Health is a medical device company, not a technology company in the traditional sense. Founded in 2010, it develops and commercializes the Jada® System, a non-invasive medical device designed to prevent postpartum hemorrhage (PPH)—the leading cause of maternal death globally[2][5].
Alydia Health addresses one of the most critical challenges in maternal healthcare: excessive bleeding after childbirth. The company's mission is to make childbirth safer for all mothers by providing an innovative solution to postpartum hemorrhage, a condition that claims one woman's life every four minutes globally[2].
The Jada System works by encouraging the body's natural postpartum response—collapsing the uterus to its correct size to stop bleeding[2]. Unlike other available treatments for uterine atony, this approach is physiologic and non-invasive. In a pilot study of 10 patients published in *Obstetrics & Gynecology*, the device rapidly controlled postpartum bleeding in all patients within two minutes[2].
Alydia Health serves hospitals and maternal healthcare providers in developed and developing markets. The company's growth trajectory reflects strong market validation: it raised $10M in Series B financing led by Global Health Investment Fund[2], completed its pivotal PEARLE IDE clinical trial[1], and ultimately achieved FDA 510(k) clearance—a critical regulatory milestone for medical device commercialization[6].
Alydia Health was founded in 2010 at Cal Poly with a vision rooted in addressing maternal mortality[7]. The company was originally called InPress Technologies before being renamed to better reflect its mission[2]. The name "Alydia" drew inspiration from Eileithyia, the Greek goddess of childbirth, symbolizing the company's commitment to supporting mothers[2].
The company's early momentum came from strong clinical validation. Its pilot study demonstrated rapid and effective hemorrhage control, which provided the foundation for advancing to larger clinical trials[2]. By 2020, Alydia had completed enrollment of its pivotal PEARLE IDE study, positioning the company for regulatory approval and market entry[1].
Alydia Health operates at the intersection of maternal health innovation and gender-focused healthcare investment. Postpartum hemorrhage remains a leading cause of maternal mortality despite being largely preventable in developed healthcare systems[5]. The company's success reflects growing recognition that women's health has historically been underfunded and under-innovated.
The acquisition by Organon in June 2021 for $240 million[3][6] signals institutional validation of the market opportunity. Organon explicitly positioned itself as a leader in women's health, with Alydia as a cornerstone acquisition[8]. This move demonstrates how maternal health innovations can attract significant capital when they address clear clinical needs and have strong regulatory pathways.
The timing of Alydia's growth coincided with increased awareness of maternal mortality disparities in the United States, where rates tripled between 1993 and 2014[3]. The company's focus on both developed and developing markets reflects the dual challenge: preventing deaths in low-resource settings while reducing morbidity (transfusions, hysterectomies) in wealthier countries[2][5].
Alydia Health's journey from startup to $240M acquisition represents a successful path through the medical device commercialization gauntlet—a process that typically takes over a decade[3]. Under Organon's ownership, the company is positioned to expand the Jada System into Europe and other developed markets while simultaneously increasing access in underdeveloped regions[5].
The company's evolution underscores a broader shift: women's health is becoming a strategic priority for large healthcare companies. As Organon continues to build its women's health portfolio, Alydia's technology will likely serve as a flagship example of how targeted innovation can address maternal mortality at scale. The real measure of success will be adoption rates in low-income countries, where the burden of postpartum hemorrhage remains highest.
Alydia Health has raised $24.0M across 2 funding rounds. Most recently, it raised $14.0M Series C in July 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2020 | $14.0M Series C | Adjuvant Capital | |
| Aug 1, 2018 | $10.0M Series B | Adjuvant Capital, Fusion Fund, Sonder Capital, Maurice Ferre |